Will developments in allogeneic transplantation influence treatment of adult patients with sickle cell disease?

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 1, 2004, Pages 23-31

  Chakrabarti, Suparno ^a,b   Bareford, David ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

Alemtuzumab; Haploidentical; Mixed chimerism; Nonmyeloablative transplantation; Sickle cell disease

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD28 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; HYDROXYUREA; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHIMERA; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE SEVERITY; DONOR; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; LIFE EXPECTANCY; NONHUMAN; PAIN; QUALITY OF LIFE; SICKLE CELL ANEMIA;

ADULT; AGE FACTORS; ANEMIA, SICKLE CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0742271415     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.09.004     Document Type: Article

References (54)

1. Leikin S.L. Gallagher D. Kinney T.R. Sloane D. Klug P. Rida W. Mortality in children and adolescents with sickle cell disease: Cooperative Study of Sickle Cell Disease Pediatrics 84 1989 500-508
2. Platt O.S. Brambilla D.J. Rosse W.F. et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death N Engl J Med. 330 1994 1639-1644
3. Perronne V. Roberts-Harewood M. Bachir D. et al. Patterns of mortality in sickle cell disease in adults in France and England Hematol J. 3 2002 56-60
4. Steinberg M.H. Barton F. Castro O. et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment JAMA 289 2003 1645-1651
5. Johnson F.L. Look A.T. Gockerman J. et al. Bone marrow transplantation in a patient with sickle cell anemia N Engl J Med. 311 1984 780-783
6. Walters M.C. Storb R. Patience M. et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease Blood 95 2000 1918-1924
7. Vermylen C. Cornu G. Ferster A. et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium Bone Marrow Transplant. 22 1998 1-6
8. Bernaudin F. Vernant J.P. Vilmer E. et al. Results of myeloablative allogeneic stem cell transplant for severe sickle cell disease in France Blood 100 suppl 1 2002 5a
9. Walters M.C. Sullivan K.M. Bernaudin F. et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia Blood 85 1995 879-884
10. Mentzer W.C. Heller S. Pearle P.R. Hackney E. Vichinsky E. Availability of related donors for bone marrow transplantation in sickle cell anemia Am J Pediatr Hematol Oncol. 16 1994 27-29
11. Walters M.C. Patience M. Leisenring W. et al. Barriers to bone marrow transplantation for sickle cell anemia Biol Blood Marrow Transplant. 2 1996 100-104
12. Kean L.S. Durham M.M. Adams A.B. et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation Blood 99 2002 1840-1849
13. McSweeney P.A. Storb R. Mixed chimerism: preclinical studies and clinical applications Biol Blood Marrow Transplant. 5 1999 192-203
14. McSweeney P.A. Niederwieser D. Shizuru J.A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
15. Giralt S. Thall P.F. Khouri I. et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
16. Slavin S. Nagler A. Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
17. Graido-Gonzalez E. Doherty J.C. Bergreen E.W. et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis Blood 92 1998 2551-2555
18. Ferrera J.L.M. Antin J.H. Pathophysiology of graft-versus-host disease In: Thomas E.D. Blume K.G. Forman S.J. (Eds.), Haematopoetic Stem Cell Transplantation 1999 305-315 Blackwell Scientific Publications Boston
19. Easaw S.J. Lake D.E. Beer M. et al. Graft-versus-host disease : Possible higher risk for African American patients Cancer 78 1996 1492-1497
20. Klingemann H.G. Deeg H.J. Self S. Thomas E.D. Storb R. Is race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant. 1 1986 87-94
21. Walters M.C. Patience M. Leisenring W. et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia Biol Blood Marrow Transplant. 7 2001 665-673
22. Iannone R. Luznik L. Engstrom L.W. et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia Blood 97 2001 3960-3965
23. Iannone R. Casella J.F. Fuchs E.J. et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia Biol Blood Marrow Transplant. 9 2003 519-528
24. van Besien K. Bartholomew A. Stock W. et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease Bone Marrow Transplant. 26 2000 445-449
25. van Besien K. Stock W. Smith S. et al. Allogeneic stem cell transplantation with fludarabine melphalan and campath conditioning for adults with advanced sickle cell disease Blood 100 suppl 1 2002 430b
26. Krishnamurti L. Blazar B.R. Wagner J.E. Bone marrow transplantation without myeloablation for sickle cell disease N Engl J Med. 344 2001 68
27. Schleuning M. Stoetzer O. Waterhouse C. Schlemmer M. Ledderose G. Kolb H.J. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease Exp Hematol. 30 2002 7-10
28. Walters M.C. Stem cell transplantation for sickle cell disease: how and when to intervene Hematology (American Society of Haematology Education Program Book) 2002 10-34
29. Barrett J. Childs R. Non-myeloablative stem cell transplants Br J Haematol. 11 2000 6-17
30. Kottaridis P.D. Milligan D.W. Chopra R. et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
31. Kreiter S. Winkelmann N. Schneider P.M. et al. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation Bone Marrow Transplant. 28 2001 157-161
32. Chakrabarti S. McDonald D. Milligan D.W. T cell-depleted nonmyeloablative stem cell transplantation: what is the optimum balance between the intensity of host conditioning and the degree of T cell depletion of the graft? Bone Marrow Transplant. 28 2001 313-314
33. Chakrabarti S. Mackinnon S. The relevance of nonmyeloablative transplantation in developing countries: the lessons from the UK experience Transplant Proc. 35 2002 172-173
34. Chakrabarti S. Mackinnon S. Chopra R. et al. High incidence of CMV infection after nonmyeloablative stem cell transplantation: potential role of CAMPATH-1H in delaying immune reconstitution Blood 99 2002 4357-4363
35. Rebello P. Cwynarsky K. Varughese M. et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients Cytotherapy 3 2001 261-267
36. Weiss L. Abdul-Hai A. Or R. Amir G. Poliiack A. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukaemia Bone Marrow Transplant. 31 2003 11-15
37. Lucarelli G. Andreani M. Angelucci E. The cure of the thalassemia with bone marrow transplantation Bone Marrow Transplant. 28 suppl 1 2001 S11-S13
38. van Besien K. Koshy M. Anderson-Shaw L. et al. Allogeneic stem cell transplantation for sickle cell disease: A study of patients' decisions Bone Marrow Transplant. 28 2001 545-549
39. Ballas S.K. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease Semin Hematol. 38 suppl 1 2001 30-36
40. La Nasa G. Giardini C. Argiolu F. et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes Blood 99 2002 4350-4356
41. Locatelli F. Rocha V. Reed W. et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease Blood 101 2003 2137-2143
42. Barker J.N. Wagner J.E. Umbilical cord blood transplantation: current state of the art Curr Opin Oncol. 14 2002 160-164
43. Aversa F. Tabilio A. Velardi A. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype N Engl J Med. 339 1998 1186-1193
44. Ruggeri L. Capanni M. Urbani E. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097-2100
45. Ruggeri L. Capanni M. Tosti A. et al. Natural killer cells : biology and application in stem-cell transplantation Cytotherapy 4 2002 445-446
46. Einsele H. Roosnek E. Rufer N. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy Blood 99 2002 3916-3922
47. Rooney C.M. Smith C.A. Ng C.Y.C. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 92 1998 1549-1555
48. Hsieh M.H. Varadi G. Flomenberg N. Korngold R. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk Biol Blood Marrow Transplant. 8 2002 303-315
49. Shimazaki C. Ochiai N. Uchida R. et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism Blood 101 2003 3334-3336
50. Tanaka J. Asaka M. Imamura M. T-cell co-signalling molecules in graft-versus-host disease Ann Hematol. 79 2000 283-290
51. Blazar B.R. Taylor P.A. Noelle R.J. Vallera D.A. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses J Clin Invest. 102 1998 473-482
52. Guinan E.C. Boussiotis V.A. Neuberg D. et al. Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med. 340 1999 1704-1714
53. Koc O.N. Lazarus H.M. Mesenchymal stem cells: heading into the clinic Bone Marrow Transplant. 27 2001 235-239
54. Panoskaltsis-Mortari A. Taylor P.A. Rubin J.S. et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury Blood 96 2000 4350-4356